market Inner Banner
  • BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ticker-arrow
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Glenmark Pharma posts robust Q4 performance
(13:36, 30 May 2026)
Revenue from operations jumped 16.8% YoY to Rs 3,760.28 crore in Q4 FY26.

Profit before tax (PBT) soared to Rs 387.77 crore in Q4 FY26 from Rs 7.97 crore in Q4 FY25. EBITDA was Rs 762.6 crore in the quarter ended March 31, 2026, with EBITDA margin for the quarter at 20.2 %.

Revenue from India business increased 8.2% to Rs 1,020 crore in Q4 FY26, compared with Rs 943 crore in Q4 FY25. Revenue from North America jumped 29.4% YoY to Rs 924.8 crore Revenue from Europe climbed 21.4% to Rs 890.7 crore. Revenue from emerging markets increased 13.7% to Rs 897.9 crore.

For the year ended March 31, 2026, the company's consolidated net profit jumped 30.06% to Rs 1,361.85 crore in FY26 compared with Rs 1,047.09 crore in FY25. Revenue from operations jumped 27.12% YoY to Rs 16,711.40 crore in FY26.

Glenn Saldanha, chairman and managing director, Glenmark Pharmaceuticals, said, 'FY26 has been a defining year in Glenmark's evolution. We delivered strong business performance while making meaningful progress against the strategic priorities that will shape our future.

The landmark AbbVie partnership validated the strength of our innovation capabilities and the global relevance of our science. During the year, we expanded our portfolio of differentiated products including the successful launches of key generic respiratory products in the US which demonstrates continued expertise in our core therapeutic areas. We also accelerated the global momentum of RYALTRIS and our collaborations during FY26 reinforced our position as the partner of choice for innovative molecule launches across markets.'

Separately, the board approved the transfer of the nebulizer brands and associated intellectual property assets to Glenmark Healthcare for Rs 223 crore. The transfer is expected to be completed on or before 30 June 2026.

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

The counter dropped 4.55% to settle at Rs 2,274.25 on the BSE.

Powered by Capital Market - Live News

.
Stock Broker Name Registration Number Registered Address Branch Address Contact Number Email id
DB (International) Stock Brokers Limited INZ000179035 (BROKING)

IN-DP-CDSL-266-2004 (DEPOSITORY)
Unit No. 210/211/211A at 2nd floor, Dalal Street Commercial Cooperative Society Ltd, Block No.53, Zone 5, Gift City, Gandhinagar, Gujarat-382355
51, Mini Market T/F Mandir Wali Gali, Yusaf Sarai, New Delhi 110016 011-35936102 greenpark@dbonline.in
C-12, DB Plaza, RDC Raj Nagar, Ghaziabad 201002 0120-4150393 ghaziabad@dbonline.in
Plot No 4, Wasme House, Film City Sector 16A, Noida – 201301 0120-4823200 compliance@dbonline.in
Out Side Jassusar Gate, Bikaner, Rajasthan – 334001 9001643408 bikaner@dbonline.in
Office No 101, City Center, Opp. High Court, M G Road, Indore 452001 9424083019 brajeshsadani@dbonline.in
203, Marshal House 25, Strand Road, Kolkata 700001 033-40055270 b032@dbonline.in
Shop No.-7, 2nd Floor, Amar Complex, Opp. Hanumaan Mandir, The Mall, Solan- 173212 6230604596 parwanoo@dbonline.in
Daga Commodities Private Limited INZ000028833 114, New Delhi House, 27 Barakhamba Road, Delhi 110001- 0120-4823200 compliance@dbonline.in
Daga Business (International) Stock Brokers (IFSC) Private Limited INZ000202436 Unit No. 228, Signature Building, Second Floor, Block 13B, Zone-1, Gift SEZ, Gandhinagar, Gujarat 382355 - 0120-4823200 compliance@dbonline.in

Disclosure regarding proprietary trading:

As required under Circular No. SEBI/MRD/SE/Cir-42/2003 dated 19.11.2003 issued by the Securities and Exchange Board of India; We hereby disclose that in addition to client based business, We are also doing proprietary trading.

Investor Grievances Email ID: investorgrievance@dbonline.in


Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and Maintained by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries | Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. | Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. | Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month........... Issued in the interest of Investors"